Healthcare League Tables?
Anyone have access to the healthcare league tables? Looked all over WSO and online and it seems p difficult to find, any help is appreciated.
Trending Content - Investment Banking Forum
| +85 | Drunk VP. How to manage? | 28 | 11h |
| +45 | How do I take my foot off the gas? (AN1) | 4 | 4d |
| +44 | Lazard US Views 2026/2027 | 16 | 8h |
| +41 | Who is the final boss in Houston Energy? (GS, JEFF or EVR) | 9 | 12h |
| +37 | Tomorrow Will Be Better | 5 | 18h |
| +34 | Moelis PCA vs Lower tier BB Coverage | 20 | 40m |
| +28 | Why Do We Turn Comments? | 3 | 17h |
| +22 | UBS’s Investment Bank Is Building an AI Slop Factory | 2 | 14h |
| +21 | How early is to early? | 9 | 1d |
| +21 | [2026 - October] Unbiased Prestige Rankings | 7 | 14h |
Career Resources
It’s something like:
Citi and Jefferies might be switched but that’s the general order, and it’s pretty similar for US/Global and M&A/all products
You’re forgetting the folks at the top - Evercore, Centerview, and a bit of PJT and Moelis
Also JPM is way ahead of GS in HC
Way ahead is a stretch, just ran a FactSet screen and GS is actually ahead when it comes to announced M&A deals for 2021. JPM does more financings which boosts up their total deal count and deal amount. JPM does fantastic, definitely the perennial favorite in the space with their HC Conference and large balance sheet. That said, GS is def no slouch and MS and BoFA aren't far behind.
To respond to your second comment about Evercore, CVP, etc...Centerview and Evercore is indeed up there, especially on the M&A standpoint. However, Moelis and PJT are still a ways off. In fact, Jefferies and Guggenheim are ahead of those two respectively. Moelis doesn't announce deal size for many of their deals given they're private and also aren't particularly active in Pharma. PJT does sporadic large deals but doesn't have consistency.
Stop speaking out of your ass, especially if you are going to hit me with ms. 2021 Americas fees by all products goes:
So Citi was lower and throw in CVP up there. If you run it by M&A volume, GS is still ahead of JPM by a sizable amount (~$60bn).
Do you have breakdown of fees for each?
Quisquam maiores excepturi eaque enim ipsum quod facere odio. Id qui ut veniam non repudiandae. Qui consequuntur error rerum adipisci voluptas magni. Cupiditate voluptatibus perferendis quis atque dolor et consequatur maxime. Totam neque tempora nulla sed ex quia voluptatum.
Corrupti ea temporibus quasi. Perferendis similique nemo ad. Nihil facilis voluptatem quo ipsa voluptas ex nam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...